NEW YORK (GenomeWeb News) – WaferGen Biosystems reported after the close of the market on Thursday a 55 percent jump in its fourth quarter revenues.

For the three months ended Dec. 31, 2013, total revenues reached $490,465, up from $316,177 in the prior-year fourth quarter. Product revenues increased to $365,465, compared to $316,177 a year ago, while license and royalty revenues in Q4 2013 were $125,000, compared to zero a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.